| Story Views | |
| Now: | |
| Last Hour: | |
| Last 24 Hours: | |
| Total: | |
Cara Therapeutics lifted by positive results from phase 2 to 3 trial results of treatment for uremic pruritus
Shares in Cara Therapeutics Inc (NASDAQ:CARA) jumped higher after the biotech group reported positive results from a trial of a treatment for uremic pruritus, a debilitating itch condition that affects patients with chronic kidney disease.
In a statement, the company said that results from Part A of a phase 2 to 3 trial of its I.V. CR845 treatment met primary and secondary endpoints for efficacy.
It noted that there are currently no approved therapies for the condition in the US.
Gil Yosipovitch, Professor of dermatology at the Miller School of Medicine and director of the Miami Itch Center at the University of Miami said: “There is an unmet medical need for an effective long-term therapy for treating this intractable pruritus and providing meaningful improvement in the quality of life of these patients under dialysis treatment.”
The company said it is planning to meet with the US Food and Drug Administration to finalise the design of Part B of the study and to start recruiting patients later this year.
CR845 is being developed for the treatment of acute and chronic pain as well as uremic pruritus.
In premarket trading in New York, Cara shares were over 15% higher at US$20.63, having gained 95% in the year to date.
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/175550/cara-therapeutics-lifted-by-positive-results-from-phase-2-to-3-trial-results-of-treatment-for-uremic-pruritus-175550.html
